A recent court decision has ostensibly made if possible for generic-drug companies to manufacture their own versions of the fish oil pill Lovaza. How does this news affect shareholders of GlaxoSmtihKline (NYSE: GSK ) , the company that sells the drug in the U.S., and how can this decision affect rivals like struggling biotech company Amarin (NASDAQ: AMRN ) ?
Analysts David Williamson and Max Macaluso discuss these topics in the following video segment from The Motley Fool's health-care show Market Checkup.
9 solid dividend stocks
One of the best parts of owning Big Pharma stocks like is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.